EuroBiotech:​​ ​​More​​ ​​Articles​​ ​​of​​ ​​Note

A pile of newspapers
Novo Seeds, MorphoSys and NeuroSearch were in the news this week.

> Targovax revealed that a supply interruption has disrupted clinical development of ONCOS-102. The setback has pushed back the data readouts from a mesothelioma trial and a pair of partnered studies by up to six months. A trial of ONCOS-102 in melanoma is still on track to deliver data late next year. Release

> Genfit kicked off pediatric development of its NASH candidate elafibranor. The action follows the European Medicines Agency’s approval of a pediatric development plan for the drug. Genfit has begun the program with juvenile toxicology studies. Release

> The Danish Supreme Court found NeuroSearch guilty of market manipulation. The charges date back to the publication of top-line data from a Phase III trial in 2010. A lower court ruled against NeuroSearch in 2014, but the company appealed. Having lost again, NeuroSearch’s board is assessing the future of the company. Release

Webinar

How ICON, Lotus, and Bioforum are Improving Study Efficiency with a Modern EDC

CROs are often at the forefront of adopting new technologies to make clinical trials more efficient. Hear how ICON, Lotus Clinical Research, and Bioforum are speeding database builds and automating reporting tasks for data management.

> Novo Seeds invested in Merozyne Therapeutics. The fund joined with Almi Invest to put up SEK 6.3 million ($684,000) to fund research into a potential treatment for congenital muscular dystrophy. Merozyne’s approach is based on the autophagy process, the discovery of which won a Nobel Prize this year. Release

> Innate Pharma posted more data from a Phase I/II trial combining lirilumab and Bristol-Myers Squibb’s Opdivo. The new data show that 41% of participants with PD-L1 expression levels of 1% or more responded to the combination. Just shy of one-quarter of the whole trial population responded. Release

> MorphoSys raised €115 million ($123 million) in a private placement. Some of the money will go toward a Phase III trial of MorphoSys’ anti-CD19 antibody MOR208 in diffuse large B cell lymphoma. Release

Suggested Articles

The $210 million fund began life by leading a $17 million series A round in Quellis Biosciences.

The nine-story building will house Amgen’s Bay Area employees when it opens early in 2022.

More than half of the participants met the primary endpoint, teeing Sanofi up to file for FDA approval of the complement C1s inhibitor.